News articles about Cytori Therapeutics (NASDAQ:CYTX) have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytori Therapeutics earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.3584915551123 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the headlines that may have effected Accern Sentiment’s scoring:

A number of analysts have recently issued reports on the company. B. Riley reaffirmed a “buy” rating and issued a $2.30 price target on shares of Cytori Therapeutics in a research note on Monday, May 15th. Zacks Investment Research raised Cytori Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 12th. ValuEngine lowered Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Maxim Group set a $10.00 price target on Cytori Therapeutics and gave the stock a “buy” rating in a research note on Saturday, May 13th.

Shares of Cytori Therapeutics (NASDAQ CYTX) opened at 0.3678 on Wednesday. The firm’s market capitalization is $11.95 million. The stock has a 50 day moving average price of $0.90 and a 200-day moving average price of $1.25. Cytori Therapeutics has a 52 week low of $0.36 and a 52 week high of $2.29.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.05. Cytori Therapeutics had a negative return on equity of 177.92% and a negative net margin of 491.71%. The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $2.32 million. During the same period last year, the business posted ($0.03) EPS. Cytori Therapeutics’s quarterly revenue was down 53.8% on a year-over-year basis. On average, analysts anticipate that Cytori Therapeutics will post ($0.83) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Cytori Therapeutics (NASDAQ:CYTX) Earns Media Sentiment Rating of 0.12” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/09/cytori-therapeutics-nasdaqcytx-earns-media-sentiment-rating-of-0-12.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Insider Buying and Selling by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.